Egypt's Digital Payments Explosion: From USD 765 Million to USD 2.9 Billion by 2033 | Ken Research

Vietnam Biotech Market Hits USD 1.5 Billion in 2023 With Bio-Manufacturing Capacity Targeted to Double by 2028: Ken Research

Vietnam is rapidly becoming a biotechnology producer, with state-backed investment programs, domestic vaccine factories under construction, and a regulatory overhaul compressing approval timelines for international biologics. As per Ken Research market modelling, the sector was valued at USD 1.5 billion in 2023 with bio-manufacturing capacity targeted to double by 2028. The Vietnam Biotech Market Report maps every structural driver in detail. This analysis is published by Ken Research, a leading market intelligence firm covering life sciences across Southeast Asia.

This analysis is based on Ken Research market modelling, government policy disclosures, and third-party healthcare-sector estimates.

USD 1.5 Billion Market in 2023 and USD 1 Billion Government Allocation: Vietnam's Biotech Investment Inflection

Vietnam's biotech sector is at an inflection point driven by coordinated state capital deployment at a scale uncommon in Southeast Asia. The market stood at USD 1.5 billion in 2023, and an additional USD 1 billion government allocation in 2024 targeted gene therapy, vaccine production, and personalized medicine capabilities. The USD 100 million Bio-Future Initiative 2024 provided an operational complement to the National Biotechnology Development Strategy 2024-2030, Northern Vietnam holds the dominant regional share due to its concentration of government institutions, research bodies, and established biotech firms. For the broader pharmaceutical ecosystem context, see the Vietnam Pharmaceuticals Market Report.

• Market Size (2023): USD 1.5 billion, with bio-manufacturing capacity targeted to double by 2028
• Government Allocation: USD 1 billion additional 2024 funding for gene therapy, vaccine production, and personalized medicine
• Bio-Future Initiative: USD 100 million dedicated budget launched in 2024 alongside the National Biotechnology Development Strategy 2024-2030
• Regional Leader: Northern Vietnam holds dominant market share; bio-pharma leads by product type and healthcare biotechnology leads by application

Vaccine Infrastructure Tops VND 2,500 Billion as VNVC Partners with Sanofi, Pfizer, and GSK

Vietnam's vaccine manufacturing investment is the most concrete expression of its biotech ambition. VNVC's new plant, commenced in May 2025, required investment exceeding VND 2,500 billion and is designed for 100 million doses per year, with technology transfer from Sanofi, Pfizer, and GSK. Vinbiocare separately scaled its capacity to 200 million doses per year in 2024. Operators tracking cold-chain readiness alongside manufacturing capacity should also evaluate the Vietnam Cold Chain for Pharmaceuticals Market.

• VNVC Vaccine Plant: Investment exceeding VND 2,500 billion, capacity of 100 million doses per year, commenced May 2025
• LEED-Certified Factory: USD 81.3 million investment in Long An province, net-zero target, partnered with Germany's Rieckermann Group
• Vinbiocare: Capacity scaled to 200 million doses per year in 2024, with Arcturus Therapeutics partnership for mRNA vaccine technology
• Biologic Drug Market: Vietnam's biologic drug segment reached USD 300 million in 2024, within a broader pharma market of USD 11.28 billion

Want the full competitive benchmarking for Vietnam's biotech and vaccine manufacturing landscape? Download Sample Report today.

How Vietnam's Regulatory Overhaul Is Accelerating Biotech Market Entry in 2025

Vietnam's regulatory environment has historically been a friction point for international biotech firms, but Decree 43/2026 halved approval timelines from 90 to 45 working days for products cleared in 5 or more OECD or G20 nations. December 2024 saw gene editing formally recognised as a breakthrough agricultural technology, and proposed Law 146/2025 would allow gene-edited organisms with no foreign DNA to self-declare rather than undergo full GMO requirements. Vietnam approved 60 biotech events for soybeans, corn, alfalfa, sugar beets, and cotton between 2014 and 2025, demonstrating a mature agricultural biotech track record. Firms tracking this regulatory trajectory should see the Vietnam Genome Editing Market Report.

• Decree 43/2026: Approval timelines halved from 90 to 45 working days for products cleared in 5+ OECD or G20 nations
• Gene Editing Breakthrough: December 2024 formal designation; Law 146/2025 proposes self-declaration pathway for gene-edited organisms with no foreign DNA
• Agricultural Track Record: 60 biotech events approved across five major crop types between 2014 and 2025
• Registration Backlog: 3,500+ pharma products awaiting registration, underscoring the commercial urgency of faster approval timelines

Workforce Gap and Equipment Import Dependency: The Structural Risks in Vietnam's Biotech Scale-Up

Vietnam's biotech ambition is credible, but two structural constraints threaten execution timelines. Only 2,000+ biotech graduates entered the workforce in 2024 against industry demand that far exceeds this pipeline, and more than 50% of biotech machinery is still imported, creating both cost and supply chain exposure. These risks are partially offset by USD 370 million in pharma FDI in 2023 and a domestic population exceeding 100 million, which provides both demand scale and rationale for sustained inbound capital.

• Workforce Gap: Only 2,000+ biotech graduates in 2024 vs actual industry demand, constraining scale-up timelines
• Import Dependency: Over 50% of biotech machinery imported, creating cost and supply chain exposure for domestic operators
• FDI Inflow: Vietnam pharma attracted USD 370 million in FDI in 2023, reflecting sustained international confidence
• Demand Scale: Vietnam's population exceeds 100 million, providing one of Southeast Asia's largest domestic healthcare demand bases

Ready to access full market sizing, regulatory tracker, and competitive landscape? Vietnam Biotech Market Report delivers segment-level forecasts through 2028.

Conclusion

Vietnam's biotech market has moved from policy aspiration to capital deployment: USD 1.5 billion in 2023, a targeted doubling of bio-manufacturing by 2028, and approval timelines being halved by regulatory reform. The combination of USD 1 billion+ state investment, domestic vaccine plants targeting 100 million+ dose annual capacity, and a biologic drug market already at USD 300 million makes Vietnam one of Southeast Asia's more credible biotech growth stories. The full breakdown is in the Vietnam Biotech Market Report from Ken Research.

Frequently Asked Questions

Q1: What is the current size of the Vietnam biotech market?

The Vietnam biotech market was valued at USD 1.5 billion in 2023, with bio-manufacturing capacity targeted to double by 2028. The government allocated an additional USD 1 billion for biotech capabilities in 2024, and the Bio-Future Initiative added a dedicated USD 100 million operational budget. The biologic drug segment reached USD 300 million in 2024.

Q2: Which segments dominate the Vietnam biotech market?

Bio-pharma leads by product type and healthcare biotechnology leads by application. Northern Vietnam holds the largest regional share. Agricultural biotech is also expanding, with 60 biotech events approved between 2014 and 2025. For advanced therapeutic pipeline data, the Vietnam Antisense RNAi Therapeutics Market provides pipeline context.

Q3: How is Vietnam's regulatory environment changing for biotech companies?

Decree 43/2026 halved approval timelines from 90 to 45 working days for products cleared in 5+ OECD or G20 nations. The National Biotechnology Development Strategy 2024-2030 is the overarching policy framework, and Law 146/2025 proposes a self-declaration pathway for gene-edited organisms with no foreign DNA. Vietnam's pharma sector has 3,500+ products in registration backlog, making faster timelines a material commercial issue.

Q4: Who are the key domestic players in Vietnam's biotech industry?

Key operators include Vinbiocare (Hanoi), which scaled to 200 million doses per year in 2024; VNVC, which invested over VND 2,500 billion in a new vaccine plant with technology transfer from Sanofi, Pfizer, and GSK; Nanogen Pharmaceutical Biotechnology JSC (HCMC, founded 1997, developed Nanocovax vaccine); Vabiotech (Hanoi); and Mekophar Chemical Pharmaceutical JSC (HCMC).

Q5: What are the main structural risks for investors in Vietnam's biotech sector?

Two constraints stand out: a workforce gap with only 2,000+ biotech graduates in 2024 vs industry demand, and over 50% of biotech machinery still imported. These risks are partially offset by USD 370 million in pharma FDI in 2023 and a domestic population exceeding 100 million.

For the full competitive benchmarking, segment-level forecasts, and regional breakdown, access the Vietnam Biotech Market Report from Ken Research, a leading market intelligence firm covering life sciences across Southeast Asia.